Xiaojin Wang

机构：China Pharmaceutical University, Zhejiang Yongning Pharma (China)

发表论文 4 篇 · 总被引 37 次 · h-index 4

代表论文

• Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors (2019 · Bioorganic & Medicinal Chemistry · 被引 22)
• Discovery of TQ-3959 as a Potent andOrally Bioavailable BTK PROTAC Degrader Incorporating a Novel Benzisoxazole-BasedCRBN Ligand for the Treatment of B-Cell Malignancies (2025 · Journal of Medicinal Chemistry · 被引 7)
• Design, synthesis, and biological evaluation of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-one derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors (2025 · Bioorganic Chemistry · 被引 4)
• Abstract 400: Preclinical development of TQB3019: A potent and selective oral BTK degrader leveraging the OAPD® platform to overcome acquired resistance mutations (2025 · Cancer Research · 被引 4)